Jason Lettmann

Partner

Mr. Lettmann has served as ALX Chief Executive Officer since September 2023 and as a Board member since April 2020. He previously served as a member of ALX Board of directors from March 2015 to May 2017. Previously, Mr. Lettmann was a General Partner of Lightstone Ventures from March 2012 to July 2023 and a Partner at Morgenthaler Ventures, a venture capital and private equity firm, since June 2009. He previously served as Chief Executive Officer of Promedior Inc., a biotechnology company acquired by Roche, from January 2019 to February 2020 and as Vice President at Split Rock Partners, a venture capital firm, from June 2006 to June 2009. Mr. Lettmann has been a member of the board of directors of several public and privately held companies, including Ra Pharmaceuticals, a clinical-stage pharmaceutical company acquired by UCB.

Education:

Jason holds an M.B.A. with distinction from the University of Michigan’s Ross School of Business and a B.A. with honors from the University of Iowa.

Focus:

Life Sciences/Medical Devices